×

Merge Reports First Quarter Financial Results

CHICAGO, April 28, 2015 (GLOBE NEWSWIRE) -- Merge Healthcare Incorporated (Nasdaq:MRGE), a leading provider of health information systems for medical imaging, interoperability, and communication, today announced its financial and business results for the first quarter of 2015.

"Merge achieved strong sales momentum in the first quarter of the year in spite of a traditionally slow time of the year and the acquisition of D.R. Systems, Inc. in the quarter. Exclusive of the limited contribution from D.R. Systems, our healthcare segment bookings increased 60% over the first quarter of 2014," said Justin Dearborn, chief executive officer of Merge Healthcare. "Our sales results were heavily influenced by increased traction in our large hospital system installed base and a few large net new hospital wins. Increased contract volume within our hospital market and cross sell opportunities into our newly acquired D.R. Systems installed base of more than 200 clients give us confidence that we can exceed revenue of $248 million, which aligns with our current covering analysts' 2015 average revenue estimates."

Financial Summary:

  • GAAP net sales increased 7% to $54.4 million in the first quarter of 2015 compared to $50.9 million in the first quarter of 2014;
  • GAAP net income in the first quarter of 2015 was $17.7 million compared to $0.3 million in the first quarter of 2014, primarily due to $16.8 million of net benefits and costs associated with the acquisition of D.R. Systems, the vast majority of which relates to the release of $18.4 million of tax asset valuation reserves in 2015 which reflect additional value unlocked in the corporate tax structure as a result of the acquisition;
  • Adjusted net income increased 14% to $4.9 million (or $0.05 per share) in the first quarter of 2015 compared to $4.3 million (or $0.04 per share) in the first quarter of 2014;
  • Adjusted EBITDA was $10.5 million in the first quarter of 2015 compared to $10.2 million in the first quarter of 2014; and
  • Cash balance increased to $24.8 million as of March 31, 2015, compared to $19.8 million, as of March 31, 2014, an increase of 25%, inclusive of the $13 million spent in February 2015 to acquire D.R. Systems, Inc.

Business Highlights:

  • Launched new business, iConnect® Network Services, to support hospitals' and health systems' need to connect clinical decision-making, economic outcomes, and patient populations through online ordering, automated prior-authorization, and real-time electronic distribution of exam results to referring healthcare providers;
  • Signed 14 enterprise-level imaging deals at a combination of large hospitals and multi-site health systems in the first quarter of 2015;
  • Displaced competitive imaging products with Merge solutions at a combination of more than 40 hospitals and health systems in the first quarter of 2015; and
  • Increased the number of active trials on eClinicalOS™ to 505 at the end of the first quarter of 2015, or by 62%, compared to 311 active trials at the end of the first quarter of 2014. Increased active customers on the platform to 125 as of the end of the first quarter 2015, or 43%, compared to 87 customers at the end of the first quarter 2014.

Quarter Results:

Results compared to the same quarter in the prior year on a GAAP basis are as follows (in millions, except per share data):

Q1 2015 Q1 2014
Net sales $ 54.4 $ 50.9
Operating income 3.8 4.4
Net income 17.7 0.3
Net income per diluted share $ 0.11 $ 0.00
Cash balance at period end $ 24.8 $ 19.8

Non-GAAP results and other measures compared to the same quarter in the prior year are as follows (in millions, except percentages and per share data):

Q1 2015 Q1 2014
Non-GAAP results
Adjusted net income $ 4.9 $ 4.3
Adjusted EBITDA 10.5 10.2
Adjusted net income per diluted share $ 0.05 $ 0.04
Other measures
Subscription, maintenance & EDI revenue as % of net sales 65.1% 65.9%
Days sales outstanding 79 90

A reconciliation of GAAP net income to adjusted net income and adjusted EBITDA is included after the financial information below. See "Explanation of Non-GAAP Financial Measures" for definitions of each of these non-GAAP measures and the reason management believes that the adjustments made to arrive at the non-GAAP financial measures provide useful information to investors.

Operating Group Results:

Results (in millions) for our operating groups are as follows:

Three Months Ended March 31, 2015
Healthcare DNA Corporate/
Other
Total
Net sales:
Software and other $ 13.1 $ 3.7 $ 16.8
Service 7.2 2.3 9.5
Maintenance 28.0 0.1 28.1
Total net sales 48.3 6.1 54.4
Gross Margin 28.2 4.0 32.2
Gross Margin % 58.4% 65.6% 59.2%
Expenses 22.1 3.5 25.6
Segment income $ 6.1 $ 0.5 $ 6.6
Operating Margin % 13% 8% 12%
Net corporate/other expenses (1) $ 7.3 7.3
Income (loss) before income taxes (0.7)
Adj. EBITDA reconciling adjustments 5.4 0.6 5.2 11.2
Adjusted EBITDA $ 11.5 $ 1.1 $ (2.1) $ 10.5
Adjusted EBITDA % 23.8% 18.0% 19.3%
(1) Net corporate/other expenses include public company costs, corporate administration costs, acquisition-related expenses and net interest expense.
Net Sales in the Three Months Ended
March 31, 2015
Healthcare DNA Total
Revenue Source $ % $ % $ %
Maintenance & EDI $ 28.0 58.0% $ 0.1 1.6% $ 28.1 51.7%
Subscription 1.3 2.7% 6.0 98.4% 7.3 13.4%
Non-recurring 19.0 39.3% -- 0.0% 19.0 34.9%
Total $ 48.3 100.0% $ 6.1 100.0% $ 54.4 100.0%
88.8% 11.2%

Explanation of Non-GAAP Financial Measures:

We report our financial results in accordance with U.S. generally accepted accounting principles, or GAAP. This press release includes certain non-GAAP financial measures to supplement this GAAP information. Non-GAAP measures are not an alternative to GAAP and may be different from and directly comparable with non-GAAP measures used by other companies. A quantitative reconciliation of GAAP net income available to common shareholders to adjusted net income and adjusted EBITDA is included after the financial information included in this press release.

Management believes that the presentation of non-GAAP results, when shown in conjunction with corresponding GAAP measures, provides useful information to it and investors regarding financial and business trends related to results of operations, because certain charges, costs and expenses reflect events that are not essential to recurring business operations. In addition, management believes these non-GAAP measures provide investors useful information regarding the underlying performance of the post-acquisition business operations when compared to the pre-acquisition results of Merge and any significant acquired company. Purchase accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments that are provided and discussed herein. Further, management believes that these non-GAAP measures improve its and investors' ability to compare Merge's financial performance with other companies in the technology industry. Management also uses financial statements that exclude these charges, costs and expenses for its internal budgets. While GAAP results are more complete, these supplemental metrics are offered since, with reconciliations to GAAP, they may provide greater insight into our financial results. Management does not intend for the presentation of these non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP.

Additional information regarding the non-GAAP financial measures presented herein is as follows:

  • Subscription revenue is comprised of software, hardware and professional services (including installation, training, etc.) contracted with and payable by the customer over a number of years. As such, the revenue from these transactions is recognized ratably over an extended period of time. These types of arrangements will include monthly payments (including leases), SaaS and transaction-based clinical trial contracts, renewable annual software agreements (with very high renew rate), to specify a few contract methods, and may include minimum volume or dollar commitments.
  • Non-recurring revenue is comprised of perpetual software license sales and includes software, hardware and professional services (including installation, training and consultative engineering services).
  • Adjusted net income consists of GAAP net income available to common stockholders, adjusted to exclude (a) preferred stock dividends (b) share-based compensation expense, (c) restructuring and other costs, (d) one-time tax benefits related to acquisitions (e) preferred stock accretion of dividend equivalents, (f) acquisition-related amortization, (g) cost of acquisitions, (h) acquisition-related sales adjustments, and (i) acquisition-related cost of sales adjustments.
  • Adjusted EBITDA adjusts GAAP net income available to common stockholders for the items considered in adjusted net income as well as (a) remaining depreciation and amortization, (b) net interest expense, (c) income tax expense (benefit).

Management has excluded certain items from non-GAAP adjusted net income because it believes (i) the amount of certain expenses in any specific period may not directly correlate to the underlying performance of business operations and (ii) the adjustment facilitates comparisons of pre-acquisition results to post-acquisition results. In addition, certain adjustments are described in more detail below:

  • Acquisition-related amortization expense is a non-cash expense arising from the acquisition of intangible assets in connection with significant acquisitions. Management excludes acquisition-related amortization expense from non-GAAP adjusted net income because it believes such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets.
  • Share-based compensation expense is a non-cash expense arising from the grant of stock awards to employees and is excluded from non-GAAP adjusted net income because management believes such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants to new employees resulting from acquisitions.
  • Acquisition-related sales and costs of sales adjustments reflect the fair value adjustment to deferred revenues acquired in connection with significant acquisitions. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin to perform services-related software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the date the acquisition was completed. Management adds back this deferred revenue adjustment, net of related costs, for adjusted net income and adjusted EBITDA because it believes the inclusion of this amount directly correlates to the underlying performance of operations and facilitates comparisons of pre-acquisition to post-acquisition results.
  • Fully diluted shares as used in our non-GAAP measures includes (a) GAAP weighted shares outstanding, (2) GAAP incremental shares from the assumed exercise of stock options and the assumed lapse of restrictions on restricted stock awards and (3) preferred shares on an if-converted basis adjusted for the period of time that the preferred shares are outstanding. For the current period, preferred shares were outstanding for 35 of the 90 days in the quarter.

Notice of Conference Call:

Merge will host a conference call at 8:30 AM ET on Tuesday, April 28, 2015. The call will address first quarter results and will provide a business update on the company's market outlook and strategies for 2015.

Participants may preregister for this teleconference at http://emsp.intellor.com?p=419634&do=register&t=8.Upon registration, a confirmation page will display dial-in numbers and a unique PIN, and the participant will also receive an email confirmation with this information.

A replay via the Internet or phone will be available after the call at http://www.merge.com/Company/Investors/Conference-Call-Info.aspx.

About Merge

Merge is a leading provider of innovative enterprise imaging, interoperability and clinical systems that seek to advance healthcare. Merge's enterprise and cloud-based technologies for image intensive specialties provide access to any image, anywhere, any time. Merge also provides clinical trials software with end-to-end study support in a single platform and other intelligent health data and analytics solutions. With solutions that have been used by providers for more than 25 years, Merge is helping to reduce costs, improve efficiencies and enhance the quality of healthcare worldwide. For more information, visit merge.com and follow us @MergeHealthcare.

Cautionary Notice Regarding Forward-Looking Statements

The matters discussed in this press release may include forward-looking statements, which could involve a number of risks and uncertainties. When used in this press release, the words "will," "believes," "intends," "anticipates," "expects" and similar expressions are intended to identify forward-looking statements. Actual results could differ materially from those expressed in, or implied by, such forward-looking statements. The potential risks and uncertainties include those risks and uncertainties included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the SEC and are available on our investor relations website at merge.com and on the SEC website at www.sec.gov. Except as expressly required by the federal securities laws, Merge undertakes no obligation to update such factors or to publicly announce the results of any of the forward-looking statements.

MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
March 31, December 31,
2015 2014
Current assets:
Cash (including restricted cash) $ 24,784 $ 42,531
Accounts receivable, net 47,877 51,300
Inventory 6,483 5,686
Prepaid expenses 5,551 3,690
Deferred income taxes 564 1,131
Other current assets 8,746 11,110
Total current assets 94,005 115,448
Property and equipment, net 5,193 4,079
Purchased and developed software, net 42,248 14,585
Other intangible assets, net 34,706 17,956
Goodwill 267,263 214,374
Deferred income taxes 5,211 5,396
Other assets 2,502 2,499
Total assets $ 451,128 $ 374,337
Current liabilities:
Accounts payable $ 20,972 $ 21,072
Current maturities of long-term debt 11,750 11,750
Accrued wages 6,795 11,169
Restructuring accrual 1,165 --
Other current liabilities 3,502 4,996
Deferred revenue 63,206 53,184
Total current liabilities 107,390 102,171
Long-term debt, less current maturities, net of unamortized discount 210,352 213,676
Deferred income taxes 3,769 4,025
Deferred revenue 503 1,091
Income taxes payable 1,114 1,109
Other liabilities 1,757 1,664
Total liabilities 324,885 323,736
Series A convertible preferred stock 50,000 --
Total Merge shareholders' equity 68,728 50,115
Noncontrolling interest 7,515 486
Total shareholders' equity 76,243 50,601
Total liabilities and shareholders' equity $ 451,128 $ 374,337
MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except for share and per share data)
(unaudited)
Three Months Ended
March 31,
2015 2014
Net sales
Software and other $ 16,802 $ 15,083
Professional services 9,484 10,489
Maintenance and EDI 28,117 25,331
Total net sales 54,403 50,903
Cost of sales
Software and other 6,182 6,101
Professional services 6,764 6,347
Maintenance and EDI 7,800 6,963
Depreciation and amortization 1,481 1,595
Total cost of sales 22,227 21,006
Gross margin 32,176 29,897
Operating costs and expenses:
Sales and marketing 8,978 8,007
Product research and development 8,228 7,580
General and administrative 7,512 7,360
Acquisition-related expenses 351 26
Restructuring and other expenses 1,178 --
Depreciation and amortization 2,099 2,482
Total operating costs and expenses 28,346 25,455
Operating income 3,830 4,442
Other expense, net (4,526) (4,136)
Income (loss) before income taxes (696) 306
Income tax benefit (18,391) (19)
Net income 17,695 325
Less: noncontrolling interest's share (76) 2
Net income attributable to Merge 17,771 323
Less: preferred stock dividends and dividend equivalents related to accretion 5,328 --
Net income available to common shareholders $ 12,443 $ 323
Net income per share - basic $ 0.11 $ 0.00
Weighted average number of common shares outstanding - basic 96,616,916 94,656,786
Net income per share - diluted $ 0.11 $ 0.00
Weighted average number of common shares outstanding - diluted 96,616,916 95,996,566
MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months Ended
March 31,
2015 2014
Cash flows from operating activities:
Net income $ 17,695 $ 325
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 3,580 4,077
Share-based compensation 1,265 1,530
Amortization of debt issuance costs & discount 222 492
Provision for doubtful accounts receivable and allowances, net of recoveries 290 525
Deferred income taxes (18,320) 279
Net change in assets and liabilities (3,981) 2,620
Net cash provided by operating activities 751 9,848
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired (63,059) --
Purchases of property, equipment and leasehold improvements (1,248) (333)
Purchased technology and capitalized software development (393) (766)
Change in restricted cash 23 160
Net cash used in investing activities (64,677) (939)
Cash flows from financing activities:
Proceeds from issuance of preferred stock 50,000 --
Stock issuance cost paid (288) --
Preferred stock dividends (413) --
Principal payments on term loans (2,938) (8,592)
Waiver and amendment costs paid (573) --
Principal payments on capital leases (140) (167)
Proceeds from exercise of stock options and employee stock purchase plan 578 51
Net cash provided by (used in) financing activities 46,226 (8,708)
Effect of exchange rate changes on cash (24) --
Net (decrease) increase in cash and cash equivalents (17,724) 201
Cash and cash equivalents, beginning of period (net of restricted cash) (1) 42,322 19,337
Cash and cash equivalents, end of period (net of restricted cash) (2) $ 24,598 $ 19,538
(1) Restricted cash of $209 and $392 as of December 31, 2014 and 2013, respectively.
(2) Restricted cash of $186 and $232 as of March 31, 2015 and 2014, respectively.
MERGE HEALTHCARE INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NET INCOME AVAILABLE TO COMMON SHAREHOLDERS TO ADJUSTED EBITDA
(in thousands, except for share and per share data)
(unaudited)
Three Months Ended
March 31,
2015 2014
Net income available to common shareholders of Merge $ 12,443 $ 323
Preferred stock dividend 413 --
Share-based compensation expense 1,265 1,530
Restructuring and other 1,178 --
Items associated with significant acquisitions:
Tax benefits (18,393) --
Preferred stock accretion of dividend equivalents 4,915 --
Amortization of significant intangibles 2,185 2,247
Costs of acquisitions 351 26
Sales adjustments 632 162
Cost of sales adjustments (120) (25)
Adjusted net income 4,869 4,263
Depreciation and amortization 1,395 1,830
Net interest expense 4,258 4,161
Income tax expense (benefit) 2 (19)
Adjusted EBITDA $ 10,524 $ 10,235
Adjusted net income per share - diluted $ 0.05 $ 0.04
Non-GAAP fully diluted share count (1) 104,083,899 95,996,566
(1) Includes convertible preferred stock on an if-converted basis for the period outstanding

CONTACT: Media Contact: Michael Klozotsky Vice President, Corporate Marketing 312.946.2535 Michael.Klozotsky@merge.com

Source:Merge Healthcare